飞驰加速器vpm-香蕉加速器官网正版
Leveraging a broad innovation network, our venture team identifies transformational healthcare ideas at leading research labs and medical centers, then works with scientific founders to quickly hit development milestones.
飞驰加速器vpm-香蕉加速器官网正版
We’re not your typical healthcare VC firm. Through our strategic investments and partnerships, ShangPharma Innovation is focused on filling the critical investment gap that exists for earliest-stage therapeutic breakthroughs.
飞驰加速器vpm-香蕉加速器官网正版
飞驰加速器vpm-香蕉加速器官网正版
飞驰加速器vpm-香蕉加速器官网正版
/in Media, Media Coverage, 手机app加速器 /by shawnCAMBRIDGE, England and HOUSTON and SOUTH SAN FRANCISCO, Calif., Nov. 6, 2024 /PRNewswire/ — Artios Pharma Limited (Artios), The University of Texas MD Anderson Cancer Center (MD Anderson) and ShangPharma Innovation (ShangPharma) today announce the in-licensing by Artios of a small-molecule ATR inhibitor programme, developed jointly by MD Anderson and ShangPharma. Under the agreement, Artios has exclusive rights to research, develop, manufacture and commercialize […]